Compare First Citizens BancShares Inc (FCNCA) vs Heron Therapeutics Inc (HRTX) Price & Performance

First Citizens BancShares (FCNCA) trades at $2,166.64, up 5.06% today, with a neutral technical signal and bullish moving averages. The company reported strong Q1 2026 earnings of $44.86 per share, beating estimates, and maintains a solid net income margin of 24.35%. Recent news includes a planned rebranding of Silicon Valley Bank and expansion of commercial banking capabilities.

Outlook remains stable with consistent revenue near $9.3B and profit growth. Risks include margin pressure and credit trends, but analyst consensus is a $2,320 price target with a hold-heavy rating. The stock presents a value opportunity with a low P/E of 11.94, though investor sentiment is cautious amid sector challenges.

Heron Therapeutics (HRTX) trades at $0.49, up 13.93% today, showing volatile momentum amid mixed technical signals. The company maintains strong gross margins of 71.12% but struggles with profitability, posting a net loss of $20.20 million in 2025. Recent Q1 2026 earnings missed expectations with a $0.04 loss per share, though management reaffirmed full-year guidance. Analyst consensus remains overwhelmingly bullish with 94.74% buy ratings, contrasting with a recent Zacks Strong Sell designation.

HRTX presents a high-risk opportunity with significant analyst support but persistent financial challenges. The bullish sentiment stems from potential patent developments and commercial execution, while risks include ongoing losses, competitive pressures, and the discrepancy between analyst optimism and recent negative ratings. The stock's current valuation at 0.49x sales appears reasonable if the company can achieve profitability.